DR. MARTIN D. MADAUS

Corporate Board Profile

Tech Score: 0/100

Azenta, Inc.

Filing Date	Source Excerpt
2024-12-17	Martin Madaus \| Age 65 \| (Director since January 2024) Committees: Nominating and Governance (Chair), Value Creation Other Current Public Boards: Repligen Corporation (NASDAQ: RGEN), Quanterix Corporation (NASDAQ: QTRX), Hologic, Inc. (NASDAQ: HOLX) Former Public Boards: Standard Biotools Inc. (NASDAQ: LAB), Covidien Ltd. (COV) (Acquired by Medtronic plc), Mettler-Toledo International Inc. (NYSE: MTD), Millipore Corporation (MIL) (Acquired by Merck KGaA) Education: PhD, Veterinary Medicine, Tieraerztliche Hochschule Hannover; DVM, Veterinary Medicine, Ludwig-Maximilians Universität München Career Highlights: Dr. Madaus currently serves as a Senior Operating Executive at the Carlyle Group Inc. (NASDAQ: CG), a global investment firm with $382 billion in assets under management. Dr. Madaus has notable experience in strategy, mergers and acquisitions, and commercial transformations, having served as Chairman, President and CEO of Millipore Corporation, where he led their sale to Merck KGaA (FWB:MRK) for $7.2 billion and also led the $4.2 billion leveraged buyout of Ortho Clinical Diagnostics. Dr. Madaus previously served as Chairman and CEO at Other-Clinical Diagnostics and, prior to that, served as President and CEO, N.A. of Roche Diagnostics Corp, a subsidiary of Roche Holdings AG (SWX: ROG). Key Expertise Provided to the Board: As an experienced public company CEO who has spent his career in diagnostics and life science tools, both as an executive and a board member, Dr. Madaus brings valuable operational insight and industry expertise to the Azenta Board and a proven track record of creating shareholder value in both public and private life science companies. Key Skills: Executive Leadership in Life Sciences/Healthcare, Growth Strategies and Market Expansion, Investment Management, Global Business, Public Company Director Experience, M&A and Integration Experience Compensation: $211,267 total annual compensation.

Filing Date

Source Excerpt

2024-12-17

Martin Madaus | Age 65 | (Director since January 2024) Committees: Nominating and Governance (Chair), Value Creation Other Current Public Boards: Repligen Corporation (NASDAQ: RGEN), Quanterix Corporation (NASDAQ: QTRX), Hologic, Inc. (NASDAQ: HOLX) Former Public Boards: Standard Biotools Inc. (NASDAQ: LAB), Covidien Ltd. (COV) (Acquired by Medtronic plc), Mettler-Toledo International Inc. (NYSE: MTD), Millipore Corporation (MIL) (Acquired by Merck KGaA) Education: PhD, Veterinary Medicine, Tieraerztliche Hochschule Hannover; DVM, Veterinary Medicine, Ludwig-Maximilians Universität München Career Highlights: Dr. Madaus currently serves as a Senior Operating Executive at the Carlyle Group Inc. (NASDAQ: CG), a global investment firm with $382 billion in assets under management. Dr. Madaus has notable experience in strategy, mergers and acquisitions, and commercial transformations, having served as Chairman, President and CEO of Millipore Corporation, where he led their sale to Merck KGaA (FWB:MRK) for $7.2 billion and also led the $4.2 billion leveraged buyout of Ortho Clinical Diagnostics. Dr. Madaus previously served as Chairman and CEO at Other-Clinical Diagnostics and, prior to that, served as President and CEO, N.A. of Roche Diagnostics Corp, a subsidiary of Roche Holdings AG (SWX: ROG). Key Expertise Provided to the Board: As an experienced public company CEO who has spent his career in diagnostics and life science tools, both as an executive and a board member, Dr. Madaus brings valuable operational insight and industry expertise to the Azenta Board and a proven track record of creating shareholder value in both public and private life science companies. Key Skills: Executive Leadership in Life Sciences/Healthcare, Growth Strategies and Market Expansion, Investment Management, Global Business, Public Company Director Experience, M&A and Integration Experience Compensation: $211,267 total annual compensation.

Data sourced from SEC filings. Last updated: 2026-02-03